克唑替尼耐药的G2101A突变与ALK重排的非小细胞肺癌对劳拉替尼的敏感性相关：病例报告
Crizotinib-Resistant G2101A Mutation Associated With Sensitivity to Lorlatinib in -Rearranged NSCLC: Case Report.
作者信息
Begum Parvin, Cui Wanyuan, Popat Sanjay
机构信息
Lung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Institute of Cancer Research, London, United Kingdom.
出版信息
JTO Clin Res Rep. 2022 Jul 5;3(9):100376. doi: 10.1016/j.jtocrr.2022.100376. eCollection 2022 Sep.
gene rearrangements occur in 1% to 2% of NSCLC. Acquired "on-target" mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.
基因重排在1%至2%的非小细胞肺癌（NSCLC）中发生。ROS1激酶域内获得性“靶向”突变是对一线ROS1抑制剂克唑替尼的已知耐药机制。在此，我们报告首例一线克唑替尼治疗后出现获得性G2101A耐药突变的患者，该患者对劳拉替尼有反应。反应显著但持续时间短。
Zotero 插件